Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: A 6 year follow-up analysis of a large observational database

AIDS

Volumn 21, Issue 13, 2007, Pages 1824-1826

  Mauro, Zaccarelli ^a   Federica, Forbici ^a   Patrizia, Lorenzini ^a   Francesca, Ceccherini Silberstein ^b   Valerio, Tozzi ^a   Paola, Trotta Maria ^a   Patrizia, Marconi ^a   Pasquale, Narciso ^a   Federico, Perno Carlo ^a   Andrea, Antinori ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, VIRAL; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; TREATMENT OUTCOME;

EID: 34547737586     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328273bbf5     Document Type: Article

References (9)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC, USA: Department of Health and Human Services; 10 October 2006.
2. Carpenter C, Fischl M, Gazzard B, Gatell J, Hirsch M, Katzenstein D, et al. Treatment for adult HIV infection; 2006 recommendation of the International AIDS Society - USA panel. JAMA 2006; 296:827-843.
3. Palella F Jr, Armon C, Chmiel J, Buchacz K, Novack R, Wood K, et al. Improved survival associated with use of HIV susceptibility testing among HAART-experienced and therapy-naive patients in the HIV Outpatient Study. In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007, Abstract 6660.
4. Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006; 11:553-560.
5. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089.
6. Hogg R, Bangsberg D, Lima V, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
7. Cozzi-Lepri A, Phillips A, Mocroft A, Kirk O, Ruiz L, Lundgren JD. Clinical progression according to HIV drug resistance accumulated on antiretroviral therapy in EuroSIDA. In: 10th European AIDS Conference/EACS, Dublin, 17-20 November 2005, Abstract PS 3/4.
8. Lohse N, Jørgensen L, Obel N, Gerstoft J, and the Danish HIV Cohort Study. Resistance mutations predict mortality in HIV patients with triple-class antiretroviral drug failure. In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007, Abstract 659.
9. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.